Log In
Print
BCIQ
Print
Print this Print this
 

BL-8020

  Manage Alerts
Collapse Summary General Information
Company Genoscience
DescriptionFixed-dose combination of ribavirin and hydroxychloroquine that inhibits HCV-induced autophagy in host cells
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase I/II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV infection
Regulatory Designation

Partner

BioLineRx Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today